ESMO Lifetime Achievement Award

The Dutch Cancer Institute (NKI) has won the ESMO Lifetime Achievement Award, presented by The European Society for Medical Oncology, for its `excellent translational research into breast cancer´.

Photo: ESMO Lifetime Achievement Award

The NKI has bridged the field of molecular biological research and the clinic. In particular it has developed genetic assays for breast cancer that, according to ESMO, lead to better understanding of the disease and probably to more precise and less aggressive treatment.
The ESMO award – which includes ?50,000 for research - was presented for the second time; last year it went to the Breast International Group (BIG), a platform for clinical research into breast cancer.

Apologies instead of condolences
The wife of a patient, who had been treated in the ICU of the Medisch Spectrum Twente Hospital after receiving serious burns during a barbecue accident, received a questionnaire asking her to tell the hospital management about her experience with condolences she had received. The hospital letter arrived just as her husband arrived home. Its opening sentence read: ‘Recently your husband died in the intensive care ward….’ The hospital offered its apologies … better than condolences!

31.08.2007

More on the subject:

Related articles

Photo

News • New targetable driver of growth found

Thyroid gland: unexpected key to prostate cancer treatment

An international research team has discovered a promising new therapeutic approach for aggressive prostate cancer – in the thyroid gland.

Photo

News • Manganese MOF nanoparticles

New material to make MRI contrast agents greener, safer, sharper

Metal-organic frameworks (MOFs) serve as the basis for a novel type of MRI contrast agent, which the developers hope can outperform current agents while being less toxic for the patient.

Photo

News • Synthetic peptide hydrogels

Bioengineered bone marrow model advances leukaemia research

Using a bioengineered bone marrow model, researchers were able to provide key new information on the efficacy and safety of CAR T-cell therapy for acute myeloid leukaemia (AML), the most common…

Related products

Subscribe to Newsletter